Cannabinoid Receptor Modulator Formula Ia for Pain Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain management, particularly for conditions like osteoarthritis and cancer-related pain, often rely on opioids and NSAIDs, which can have limitations in efficacy and are associated with side effects, and there is a need for alternative analgesic agents that can provide effective pain relief without these drawbacks.
Innovation Solution
A composition comprising a compound of Formula Ia or its pharmaceutically acceptable salt, solvate, hydrate, and N-oxide, combined with known analgesic, antidiabetic, osteoarthritis, and anticancer agents, is administered to provide therapeutically effective pain management by modulating cannabinoid receptors, thereby addressing both acute and chronic pain conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioids and NSAIDs are used for pain management, then pain relief efficacy is improved, but side effects increase
Solution Approach 1:
The patent segments the pain management approach by introducing a novel cannabinoid receptor modulator (Formula Ia) that acts through a different mechanism than traditional opioids and NSAIDs. This segmentation allows for effective pain relief through CB1 and CB2 receptor modulation while avoiding the side effect profile of conventional analgesics.
Solution Approach 2:
The patent employs a composite pharmaceutical composition combining the cannabinoid receptor modulator of Formula Ia with other therapeutic agents. This composite approach leverages the unique mechanism of action of the cannabinoid modulator to achieve synergistic pain relief while minimizing the harmful effects associated with single-agent therapy.
2Reliability
If higher doses of individual drugs are used to improve pain relief, then efficacy is improved, but side effects increase
Solution Approach 1:
The patent merges the cannabinoid receptor modulator of Formula Ia with known analgesic and anti-inflammatory agents in a combination therapy. This merging allows for effective pain management at lower doses of each individual component, thereby reducing the side effects that would occur with higher doses of single agents.
3Object-generated harmful factors
If alternative analgesic agents are developed, then side effects are reduced, but efficacy may be compromised
Solution Approach 1:
The patent utilizes parameter changes by modifying the chemical structure of cannabinoid receptor ligands (Formula Ia with various R1-R9 substituents) to optimize both efficacy and safety profile. The structural variations allow for fine-tuning of receptor binding affinity and selectivity, achieving effective pain relief with reduced side effects.
Data Source
AI summary
Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;